Annovis Bio Beheer
Beheer criteriumcontroles 2/4
De CEO Annovis Bio is Maria Maccecchini, benoemd in May2008, heeft een ambtstermijn van 16.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.15M, bestaande uit 31.1% salaris en 68.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 7.96% van de aandelen van het bedrijf, ter waarde $ 7.21M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 8.8 jaar.
Belangrijke informatie
Maria Maccecchini
Algemeen directeur
US$2.1m
Totale compensatie
| Percentage CEO-salaris | 31.1% |
| Dienstverband CEO | 16.5yrs |
| Eigendom CEO | 8.0% |
| Management gemiddelde ambtstermijn | 1.3yrs |
| Gemiddelde ambtstermijn bestuur | 8.8yrs |
Recente managementupdates
Recent updates
Annovis Bio To Continue Alzheimer's Disease Clinical Trials
Oct 17Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom
Sep 27Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints
Jul 08Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Jun 30Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08
Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?
Feb 23We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth
Jan 01
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$43m |
| Mar 31 2024 | n/a | n/a | -US$48m |
| Dec 31 2023 | US$2m | US$668k | -US$56m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$3m | US$636k | -US$25m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$9m | US$510k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$8m |
| Dec 31 2020 | US$1m | US$420k | -US$5m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$3m |
| Mar 31 2020 | n/a | n/a | -US$1m |
| Dec 31 2019 | US$120k | US$120k | -US$991k |
| Sep 30 2019 | n/a | n/a | -US$958k |
| Jun 30 2019 | n/a | n/a | -US$841k |
| Mar 31 2019 | n/a | n/a | -US$715k |
| Dec 31 2018 | US$155k | US$120k | -US$714k |
Compensatie versus markt: De totale vergoeding ($USD 2.15M ) Maria } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).
Compensatie versus inkomsten: De vergoeding van Maria is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Maria Maccecchini (73 yo)
16.5yrs
Tenure
US$2,145,852
Compensatie
Dr. Maria L. Maccecchini, Ph D., serves as Independent Director of Lantern Pharma Inc. from June 08, 2022. She is the Founder of Annovis Bio, Inc. and has been its Chief Executive Officer and President sin...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 16.5yrs | US$2.15m | 7.96% $ 7.2m | |
| Chief Business Officer & Director | less than a year | US$135.43k | 0.44% $ 401.3k | |
| Senior Vice President of Research & Development | 2.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Operations | 2.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Operations | 1.3yrs | geen gegevens | geen gegevens | |
| Head of Quality | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Statistics | less than a year | geen gegevens | geen gegevens |
1.3yrs
Gemiddelde duur
Ervaren management: Het managementteam van ANVS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 16.5yrs | US$2.15m | 7.96% $ 7.2m | |
| Chief Business Officer & Director | 8.8yrs | US$135.43k | 0.44% $ 401.3k | |
| Independent Chairman of the Board | 10.8yrs | US$153.92k | 11.88% $ 10.8m | |
| Chief Medical Advisor & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 7.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 3.6yrs | US$143.92k | 0.053% $ 47.9k | |
| Chairman of Scientific Advisory Board | 7.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 9.8yrs | US$135.43k | 0.048% $ 43.1k |
8.8yrs
Gemiddelde duur
71.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ANVS wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).